Access in all areas? A round-up of developments in market access and health technology assessment: part 15

In this update we examine the inaugural report of the Health Economics Methods Advisory group on defining appropriate benefits for economic evaluation and the responses it has generated. We also review recent research on the timeliness of commercial health plan coverage policy updates following US FDA label revisions, which reveals substantial delays and wide variation across plans that may limit patient access to specialty therapies.